Product Description: Voxelotor-d6 (GBT 440-d6) is deuterium labeled Voxelotor. Voxelotor (GBT 440) is a potent inhibitor of haemoglobin S (HbS) polymerization. Voxelotor has the potential for sickle cell disease (SCD) treatment[1].
Applications: Neuroscience-Neuromodulation
Formula: C19H13D6N3O3
References: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216./[2]Oksenberg D, et al. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. Br J Haematol. 2016 Oct;175(1):141-53./[3]Metcalf B, Chuang C, Dufu K, et al. Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin. ACS Med Chem Lett. 2017;8(3):321-326.
CAS Number: 2170187-39-8
Molecular Weight: 343.41
Research Area: Cardiovascular Disease
Target: Isotope-Labeled Compounds;Others
Deutsch
English
